AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12127381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight at age 9 years
Number of subjects: 5098
Study 12127381 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH children maintaining lightweight
Number of subjects: 5098
Study 12127381 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight children who entered the overweight category
Number of subjects: 5098
Study 10447791 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet advice (D)
Number of subjects: 158
Study 10447791 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise advice (E)
Number of subjects: 158
Study 10447791 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise advice (DE)
Number of subjects: 158
Study 10447791 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 158
Study 7755996 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplane probe
Number of subjects: 317
Study 7755996 — intervention group
Group type: COMPARATOR
Intervention: Biplane probe
Number of subjects: 317
Study 2276015 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydrated Hemoccult II test with retesting
Number of subjects: 3561
Study 2276015 — intervention group
Group type: COMPARATOR
Intervention: Rehydrated Hemoccult II test without retesting
Number of subjects: 3561
Study 2276015 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydrated Hemoccult II test with retesting in second screening
Number of subjects: 3561
Study 2276015 — intervention group
Group type: COMPARATOR
Intervention: Rehydrated Hemoccult II test with negative retest in second screening
Number of subjects: 3561
Study 365332 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training for 2 months
Number of subjects: 44
Study 365332 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine 240 mg/day for 5 months
Number of subjects: 44
Study 365332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29023327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) supplementation (0.2 g·kg)
Number of subjects: 10
Study 29023327 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride, NaCl)
Number of subjects: 10
Study 29723074 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal condition (23 participants)
Number of subjects: 44
Study 29723074 — intervention group
Group type: COMPARATOR
Intervention: Suppression condition (21 participants)
Number of subjects: 44
Study 28974835 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy with bone replacement material (group 2)
Number of subjects: 50
Study 28974835 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy without bone replacement material (group 1)
Number of subjects: 50
Study 28974835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 50
Study 26160221 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill desk (used for at least one hour per day for 13 months)
Number of subjects: 80
Study 26160221 — intervention group
Group type: EXPERIMENTAL
Intervention: Health consultation + Treadmill desk
Number of subjects: 80
Study 26160221 — intervention group
Group type: COMPARATOR
Intervention: Health consultation + Regular workstation
Number of subjects: 80
Study 23384207 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line filtration
Number of subjects: 807
Study 23384207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no filtration)
Number of subjects: 807
Study 21676001 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay discounting task during functional magnetic resonance imaging (fMRI)
Number of subjects: 151
Study 18037022 — intervention group
Group type: EXPERIMENTAL
Intervention: Betablocker (propranolol)
Number of subjects: 0
Study 18037022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15618337 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading
Number of subjects: 8
Study 15618337 — intervention group
Group type: COMPARATOR
Intervention: Non-loaded diet
Number of subjects: 8
Study 12183305 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 369
Study 12183305 — intervention group
Group type: COMPARATOR
Intervention: Non-epidural analgesia
Number of subjects: 369
Study 10102310 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid Philadelphia collar
Number of subjects: 20
Study 7594703 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1-infected cells in breast milk
Number of subjects: 107
Study 7594703 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe vitamin A deficiency
Number of subjects: 107
Study 1968871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (600 mg/day)
Number of subjects: 24
Study 1968871 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (1.5 g/day)
Number of subjects: 24
Study 1968871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid plus taurine (600 mg + 1.5 g/day)
Number of subjects: 24
Study 1968871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 367885 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day cimetidine
Number of subjects: 0
Study 367885 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day cimetidine
Number of subjects: 0
Study 367885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 367885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g and 2 g)
Number of subjects: 0
Study 367885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 31692851 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily for 4 weeks
Number of subjects: 0
Study 31692851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28733799 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Parents, Babies and Toddlers program with depression psychoeducation (12 weekly sessions)
Number of subjects: 61
Study 28733799 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 61
Study 25998921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Strategies To Enhance Practice)
Number of subjects: 1700
Study 25998921 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1700
Study 23508626 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of a randomized treatment sequence
Number of subjects: 6
Study 20346195 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred treatment
Number of subjects: 220
Study 20346195 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 220
Study 19769721 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GM-CSF hydrogel
Number of subjects: 90
Study 19769721 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 17901013 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy with videotape feedback
Number of subjects: 10
Study 17901013 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy only
Number of subjects: 10
Study 15605645 — intervention group
Group type: EXPERIMENTAL
Intervention: Citriodiol spray applied daily for 2 weeks to the lower extremities
Number of subjects: 111
Study 15605645 — intervention group
Group type: COMPARATOR
Intervention: No repellent used
Number of subjects: 111
Study 11552915 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine and Ursodeoxycholic acid (U + C)
Number of subjects: 44
Study 11552915 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid and placebo (U + P)
Number of subjects: 44
Study 9973779 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive imagery technique
Number of subjects: 48
Study 9973779 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation imagery technique
Number of subjects: 48
Study 9973779 — intervention group
Group type: COMPARATOR
Intervention: Control condition (discussions)
Number of subjects: 48
Study 8045061 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ultrasound (US)
Number of subjects: 76
Study 8045061 — intervention group
Group type: COMPARATOR
Intervention: Venous blood pool scintigraphy (BPS)
Number of subjects: 76
Study 3377933 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual nifedipine 10 mg
Number of subjects: 40
Study 3377933 — intervention group
Group type: COMPARATOR
Intervention: placebo capsules
Number of subjects: 40
Study 31834056 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphenadrine
Number of subjects: 124
Study 31834056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 30300378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermanual transfer training program with mirror therapy and motor imagery
Number of subjects: 47
Study 30300378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermanual transfer training program only
Number of subjects: 47
Study 30300378 — intervention group
Group type: COMPARATOR
Intervention: Sham training (dummy training without using the prosthesis simulator)
Number of subjects: 47
Study 26610333 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mcg of misoprostol administered after birth when oxytocin was not available
Number of subjects: 2466
Study 26610333 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (control arm)
Number of subjects: 2466
Study 24055414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg orally once daily on days 1-14) in combination with bortezomib (1.3 mg/m² intravenously on days 1, 4, 8, and 11)
Number of subjects: 637
Study 24055414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo orally once daily on days 1-14) in combination with bortezomib (1.3 mg/m² intravenously on days 1, 4, 8, and 11)
Number of subjects: 637
Study 24055414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 637
Study 24055414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study 21438016 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral intervention
Number of subjects: 56
Study 21438016 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 17712060 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkey cutlets soaked in red wine after heating plus 200 ml of red wine (B)
Number of subjects: 10
Study 17712060 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkey cutlets soaked in red wine prior to heating plus 200 ml of red wine (C)
Number of subjects: 10
Study 17712060 — intervention group
Group type: COMPARATOR
Intervention: Turkey cutlets supplemented by water (A)
Number of subjects: 10
Study 15343157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylenediamine tetraacetic acid (Group EA)
Number of subjects: 8
Study 15343157 — intervention group
Group type: EXPERIMENTAL
Intervention: H3PO4 (Group PA3)
Number of subjects: 8
Study 15343157 — intervention group
Group type: EXPERIMENTAL
Intervention: H3PO4 + NaOCl (Group PA120)
Number of subjects: 8
Study 15343157 — intervention group
Group type: EXPERIMENTAL
Intervention: HCl + NaOCl (Group CA)
Number of subjects: 8
Study 15343157 — intervention group
Group type: COMPARATOR
Intervention: Control (Group N)
Number of subjects: 8
Study 14510110 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 12
Study 14510110 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 12
Study 9481269 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous aPTT values
Number of subjects: 0
Study 9481269 — intervention group
Group type: COMPARATOR
Intervention: aPTT values from heparinized arterial lines
Number of subjects: 0
Study 7518480 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous infusion of substance P (11.2 pmol/min) plus adenosine (125 to 2000 micrograms/min) during intrailiac infusion
Number of subjects: 17
Study 7518480 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous infusion of substance P (11.2 pmol/min) plus adenosine (50 to 800 micrograms/min) during intracoronary infusion
Number of subjects: 17
Study 7518480 — intervention group
Group type: COMPARATOR
Intervention: Adenosine infusion (125 to 2000 micrograms/min) during intrailiac infusion
Number of subjects: 17
Study 7518480 — intervention group
Group type: COMPARATOR
Intervention: Adenosine infusion (50 to 800 micrograms/min) during intracoronary infusion
Number of subjects: 17
Study 3290870 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose regimen (1,650 mg/day)
Number of subjects: 99
Study 3290870 — intervention group
Group type: COMPARATOR
Intervention: Low-dose regimen (day 1, 1,100 mg; day 2, 825 mg)
Number of subjects: 99
Study 30041526 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (8×10^9 CFU/day for 12 weeks)
Number of subjects: 50
Study 30041526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule daily for 12 weeks)
Number of subjects: 50
Study 27175706 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV-guided fluid therapy (SVV maintained at 10%-20%)
Number of subjects: 48
Study 27175706 — intervention group
Group type: COMPARATOR
Intervention: Control group (SVV maintained at <10%)
Number of subjects: 48
Study 25069393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention consisting of plenary meetings and individual visits at construction worksites
Number of subjects: 8
Study 25069393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention consisting of questionnaires for behavioral and organizational determinants
Number of subjects: 8
Study 25069393 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation of the intervention
Number of subjects: 8
Study 23158273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole-based bismuth-containing quadruple regimen
Number of subjects: 440
Study 23158273 — intervention group
Group type: COMPARATOR
Intervention: Esoprazole-based bismuth-containing quadruple regimen
Number of subjects: 440
Study 23158273 — intervention group
Group type: EXPERIMENTAL
Intervention: Total eradication rate
Number of subjects: 440
Study 23158273 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic improvements
Number of subjects: 440
Study 23158273 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin resistance
Number of subjects: 440
Study 20881072 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone (1 mg daily for 12 months)
Number of subjects: 21
Study 20881072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18603233 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-Auditory presentation (AV)
Number of subjects: 0
Study 18603233 — intervention group
Group type: COMPARATOR
Intervention: Visual only (VO)
Number of subjects: 0
Study 18603233 — intervention group
Group type: COMPARATOR
Intervention: Auditory only (AO)
Number of subjects: 0
Study 18603233 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-Visual (AV) condition
Number of subjects: 0
Study 16207220 — intervention group
Group type: EXPERIMENTAL
Intervention: FCS educational packages (six different packages, each containing three FCS educational sheets)
Number of subjects: 36
Study 16207220 — intervention group
Group type: EXPERIMENTAL
Intervention: FCS educational packages
Number of subjects: 36
Study 16207220 — intervention group
Group type: EXPERIMENTAL
Intervention: FCS educational materials
Number of subjects: 36
Study 11383320 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 26
Study 11383320 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 26
Study 9758075 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant acupuncture
Number of subjects: 46
Study 9758075 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant acupuncture
Number of subjects: 46
Study 9758075 — intervention group
Group type: COMPARATOR
Intervention: No-acupuncture control (nonsteroidal anti-inflammatory medication)
Number of subjects: 46
Study 7838418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estrogen plus cetyltrimethylammonium naproxenate douches
Number of subjects: 34
Study 7838418 — intervention group
Group type: COMPARATOR
Intervention: Estrogen topical therapy
Number of subjects: 34
Study 3045545 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids for 10 weeks plus daily azathioprine for one year
Number of subjects: 46
Study 3045545 — intervention group
Group type: COMPARATOR
Intervention: No immunosuppressive therapy (Control)
Number of subjects: 46
Study 3045545 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids plus azathioprine
Number of subjects: 46
Study 3045545 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 46
Study 31796677 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 70
Study 31796677 — intervention group
Group type: COMPARATOR
Intervention: Non-aerobic stretching and toning (SAT)
Number of subjects: 70
Study 30844471 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0
Study 30844471 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized diet using a machine-learning algorithm
Number of subjects: 0
Study 28506940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia group
Number of subjects: 50
Study 28506940 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 25732250 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4mg fludrocortisone
Number of subjects: 39
Study 25732250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23656203 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, modified-release tranexamic acid
Number of subjects: 0
Study 23656203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21907863 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway bypass (n=208)
Number of subjects: 315
Study 21907863 — intervention group
Group type: COMPARATOR
Intervention: Sham control (n=107)
Number of subjects: 315
Study 19541304 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled cord traction (CCT)
Number of subjects: 204
Study 19541304 — intervention group
Group type: COMPARATOR
Intervention: Hands-off management
Number of subjects: 204
Study 17116916 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program led by care managers for 238 patient-caregiver pairs at 9 intervention clinics for more than 12 months.
Number of subjects: 408
Study 17116916 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 408
Study 15648470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant group (viewed pleasant photographs)
Number of subjects: 32
Study 15648470 — intervention group
Group type: COMPARATOR
Intervention: Unpleasant group (viewed unpleasant photographs)
Number of subjects: 32
Study 11352412 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making
Number of subjects: 233
Study 11352412 — intervention group
Group type: EXPERIMENTAL
Intervention: Role mismatch
Number of subjects: 233
Study 11352412 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived role in decision making
Number of subjects: 233
Study 11352412 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive decision making by doctor or patient
Number of subjects: 233
Study 9499664 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA) and cytosine arabinoside (Ara‐C) induction therapy for patients < 65 years: Ara‐C 1 g/m2/day i.v. 6‐hour infusion on days 1‐4, IDA 10 mg/m2/day i.v. on days 1‐3.
Number of subjects: 25
Study 9499664 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA) and cytosine arabinoside (Ara‐C) induction therapy for elderly patients (>= 65 years): Ara‐C 1 g/m2/day 6 hours infusion on days 1 and 2, IDA 10 mg/m2/day i.v. on days 1 and 2.
Number of subjects: 25
Study 8190575 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol
Number of subjects: 88
Study 8190575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral albuterol
Number of subjects: 88
Study 8190575 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline
Number of subjects: 88
Study 8190575 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 88
Study 31509210 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-messaging program (MyTeen) for parents, 1 daily text message over 4 weeks
Number of subjects: 221
Study 29909907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab (CIX) 10 mg/kg alone
Number of subjects: 91
Study 29909907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab (CIX) 10 mg/kg with Cetuximab (CET) 500 mg/m2 every 2 weeks
Number of subjects: 91
Study 29909907 — intervention group
Group type: COMPARATOR
Intervention: CET alone (historical data)
Number of subjects: 91
Study 27090868 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT-301 (levodopa inhalation powder)
Number of subjects: 86
Study 27090868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 25222385 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) plus home exercise and advice (HEA) for 12 weeks
Number of subjects: 192
Study 25222385 — intervention group
Group type: COMPARATOR
Intervention: Home exercise and advice (HEA) alone for 12 weeks
Number of subjects: 192
Study 22951407 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based multidisciplinary intervention
Number of subjects: 100
Study 22951407 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 20930337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic periodontitis patients with atherosclerosis (Group A)
Number of subjects: 45
Study 20930337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic periodontitis patients without systemic disease (Group B)
Number of subjects: 45
Study 20930337 — intervention group
Group type: COMPARATOR
Intervention: Clinically healthy individuals (Group C)
Number of subjects: 45
Study 18446415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket reference including information about pain and symptom control and 1-2 didactic end-of-life teaching sessions per month.
Number of subjects: 136
Study 18446415 — intervention group
Group type: COMPARATOR
Intervention: Didactic sessions only (control group).
Number of subjects: 136
Study 17179480 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 fractions of 3 Gy (10 x 3 Gy)
Number of subjects: 297